Oncogenic CD44 is essential for pancreatic cancer tumorigenesis: A novel targeted therapeutic strategy

Figure 2 CD44 knockout effectively inhibits pancreatic cancer cell tumorigenesis and reduces cancer cell stemness. A and B: The tumorigenic capability of CD44-KO and control CD44-expressing (Ctrl) pancreatic cancer Panc-1 cells was measured by a colony formation assay; C and D: The stemness of CD44-KO and Ctrl Panc-1 cells was assessed by a cell spherical formation assay; E and F: Additionally, the effect of CD44 gene knockout on tumor growth in vivo was examined in xenograft mice as described in the methods section. The tumor volumes in the CD44-KO and Ctrl groups of xenograft mice were measured every other day; G: The tumors in the CD44-KO and Ctrl groups were collected, photographed; H: Weighed, and statistically analyzed. Data in Figure 2A-D are shown as the mean ± SD of three independent replicates. ^bP < 0.01 vs CD44-NT in an unpaired t test.